[Commentary on] Should the FDA approval process for weight-loss drugs be modified?

November 2011
American Journal of Health-System Pharmacy;11/1/2011, Vol. 68 Issue 21, p2094
Academic Journal
The author highlights that lorcaserin, a weight loss drug, was not approved for marketing by the FDA, and mentions the weight loss combination of phentermine and fenfluramine (fen–phen). He comments on the lack of options for the medical treatment of obesity, and states that many obesity treatment specialists feel the FDA process for approval of new weight-loss drugs needs to be changed. The criteria should include not just weight loss, but also the success rates for weight-loss maintenance.


Related Articles

  • Reins tightened on diet aids, products must now prove their worth. Keller, Betsy Heyman // Environmental Nutrition;Mar1994, Vol. 17 Issue 3, p1 

    Focuses on the safety of common ingredients in weight-control products. US Food and Drug Administration's scrutiny of phenylpropanolamine hydrochloride (PPA), an appetite suppressant; Ephedrine as active ingredient in the Chinese herb ma huang; Adverse reactions; Other ingredients found in...

  • New weight-loss drug far from a miracle.  // Tufts University Diet & Nutrition Letter;Jun96, Vol. 14 Issue 4, p6 

    Reports on the small-scale effects of the anti-obesity drug, Redux, which was approved by United States Food and Drug Administration. Effect of serotonin to the decrease in appetite; Commitment to significant eating habits of the dieting individual; Biological aspects of obesity; Redux's...

  • New drugs: Gaining ground on obesity? Pinkowish, Mary Desmond // Patient Care;9/15/1996, Vol. 30 Issue 14, p30 

    Presents information on anti-obesity drug dexfenfluramine. Mechanism of action in the suppression of appetite; Percent of body weight loss; Side effects; Medical risks; Dosage; US Food and Drug Administration approval for one year of continuous use.

  • Weight loss category gains competitor in Qsymia. Weinstein, Deborah // Medical Marketing & Media;Aug2012, Vol. 47 Issue 8, p10 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) of two weight loss drugs, Belviq from Arena Pharmaceuticals Inc. and Qsymia from Vivus Inc.

  • Over-the-counter diet products. Brainum, Jerry // Joe Weider's Muscle & Fitness;Sep95, Vol. 56 Issue 9, p158 

    Focuses on over-the-counter (OTC) diet aids. Phenylpropanolamine (PPA) as approved drug for weight-loss purposes by the United States Food and Drug Administration; Reason for the abolition on the use of amphetamines for the treatment of obesity; Precautions and warnings.

  • FDA approves weight-loss drug. Viebeck, Elise // Hill;7/19/2012, Vol. 19 Issue 92, p10 

    The article focuses on an approval of weight-loss drugs Belviq from Arena Pharmaceuticals Inc. and Qsymia from Vivus Inc. by the U.S. Food and Drug Administration.

  • Advisory panel votes against Qnexa. Elliott, William T. // Neurology Alert;Sep2010 Pharmacology, p2 

    The article reports that an advisory panel of the U.S. Food and Drug Administration (FDA) recommended against the approval of the combination weight-loss drug Qnexa® (phentermine/topiramate) due to safety concerns.

  • Advisory panel votes against Qnexa. Elliott, William T. // Infectious Disease Alert;Sep2010 Supplement, p2 

    The article reports on the recommendation of the U.S. Food and Drug Administration (FDA) advisory panel by a vote of 10 to 7 against approving the combination weight-loss drug Qnexa, a combination of phentermine and topiramate, because of safety concerns.

  • FDA Warning: Pharmaceuticals in "Natural" Products.  // Critical Care Alert;May2009 Pharmacology Watch, p1 

    The article warning of the U.S. Food and Drug Administration (FDA) concerning weight-loss products that contained undeclared pharmaceutical ingredients including Herbal Xenicol, Slimbionic, and Xsvelten.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics